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Aims No studies have examined the effect of mineralocorticoid receptor antagonist therapy on new-onset diabetes. In add-
ition, though the combination of diabetes and chronic heart failure (CHF) carries a poor prognosis, few studies have
examined predictors of new-onset diabetes in those with CHF.
Methods
and results
In patients with symptomatically mild CHF who participated in the placebo-controlled Eplerenone in Mild Patients
Hospitalization and Survival Study in Heart Failure, we examined the effect of the aldosterone antagonist, eplerenone,
on physician-diagnosed diabetes using univariate Cox proportional hazard analysis. To identify predictors of new-
onset diabetes (measures of glycaemia were not available), data from trial arms were combined and multivariate
Cox proportional hazard analyses and receiver operating characteristic curve analyses were conducted. At baseline,
the mean age of 1846 initially non-diabetic patients was 69 years and mean left ventricular ejection fraction was 26%.
Over 21 months, 69 (3.7%) developed diabetes (33 on eplerenone, 36 on placebo). Eplerenone had no effect on
new-onset diabetes [hazard ratio (HR) 0.94, 95% confidence interval (CI) 0.59–1.52] and no effect on the composite
of new-onset diabetes or mortality (HR 0.80, 95% CI 0.64–1.01). Independent predictors of new-onset diabetes
included digoxin therapy, higher serum alanine aminotransferase, longer duration of heart failure, current or previous
smoker, higher waist circumference, lower age, and higher systolic blood pressure with a combined c-statistic of 0.74.
Conclusions Eplerenone had no effect on new-onset diabetes in patients with CHF, but further large-scale studies are required to
address this question comprehensively. Commonly recorded parameters provided useful information for predicting
new-onset diabetes.
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Introduction
Patients with heart failure are at increased risk of developing new-
onset diabetes mellitus, and co-existent diabetes is associated with
worse heart failure symptoms, higher rates of hospitalization, and
reduced survival.1 Why the risk of incident diabetes is increased
in heart failure is uncertain, and relatively little is known about
the variables predicting this risk. To date, only the Candesartan
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in Heart Failure: Assessment of Reduction in Mortality and Morbid-
ity (CHARM) and Carvedilol Or Metoprolol European Trial
(COMET) trials have examined this question.2,3 It is known,
however, that angiotensin II receptor blockers (ARBs), and pos-
sibly angiotensin-converting enzyme (ACE) inhibitors, reduce the
risk of developing diabetes in patients with heart failure (and also
in those with hypertension and impaired glucose tolerance).4 –6 It
is therefore of interest to know whether the other type of
renin–angiotensin–aldosterone blockers used in heart failure, min-
eralocorticoid receptor (MR) antagonists, affect the risk of incident
diabetes. Data on the effect of MR antagonists on glycaemic indices
are conflicting. Treatment with the non-selective MR antagonist,
spironolactone, has consistently been associated with elevations
in haemoglobin A1c (HbA1c) in patients with and without dia-
betes,7 – 10 suggesting that spironolactone may increase the risk
of new-onset diabetes. In contrast, spironolactone has been
shown to improve insulin sensitivity in patients with non-alcoholic
fatty liver disease (NAFLD), a condition closely associated with
insulin resistance.11 Even less is known about the actions of the
more selective MR antagonist eplerenone. However, in one trial
comparing the effects of spironolactone and eplerenone in patients
with chronic heart failure, spironolactone recipients showed
increases in both HbA1c and cortisol levels, plus a fall in adiponec-
tin, whereas no changes occurred in eplerenone recipients.7
New-onset diabetes was a pre-defined secondary endpoint in
the Eplerenone in Mild Patients Hospitalization and Survival
Study in Heart Failure (EMPHASIS-HF). In this report we describe
the effect of eplerenone, compared with placebo, on new-onset
diabetes and the baseline predictors of incident diabetes.
Methods
The primary aim of EMPHASIS-HF was to investigate the effect of epler-
enone, added to evidence-based therapy, on clinical outcomes in
patients with systolic heart failure and mild symptoms [patients had to
be in New York Heart Association (NYHA) functional class II].
The design, protocol, and results of the trial are available elsewhere.12,13
Briefly, 2737 patients with mild symptoms and a left ventricular ejection
fraction ≤ 0.35 were randomized to receive either the aldosterone an-
tagonist, eplerenone (up to 50 mg daily), or placebo in addition to
recommended therapy (including an ACE inhibitor or ARB and
beta-blocker). Patients were followed up for a median of 21 months
to assess the effect on a composite outcome of cardiovascular death
or hospitalization for heart failure. Patients were seen 4 weeks after
randomization and then every 4 months during trial follow-up. All
patients provided written informed consent and the protocol was
approved by the ethics committee at each participating institution.
The trial was supported by the study sponsor, Pfizer.
Analysis population
The analysis population included all EMPHASIS-HF participants in the
full analysis set but excluding those known to have diabetes at baseline.
Diabetes status at baseline was determined from the following parts
of the study case report form: (i) significant medical condition report at
screening; (ii) the aetiology of heart failure report and prior index hos-
pitalization at screening; (iii) the medical history page; and (iv) use of
medications for diabetes in the 3 months prior to screening or at
the randomization visit.
Diagnosis of new-onset diabetes
Incident diabetes was a pre-specified secondary endpoint in
EMPHASIS-HF. Investigators were asked to check for (and report)
the occurrence of a new diagnosis of diabetes at each post-
randomization trial visit. Details of the diagnosis of diabetes [date of
diagnosis, details of the criteria for diagnosis [elevated fasting plasma
glucose ( ≥ 7.0 mmol/L), random glucose ( ≥ 11.1 mmol/L), or oral
glucose tolerance test (fasting plasma glucose ≥ 7.0 mmol/L and/or
2 h plasma glucose ≥ 11.1 mmol/L)], hypoglycaemic medication pre-
scribed, and lifestyle modifications prescribed were documented on
a specific incident diabetes case report form. Fasting blood samples
were not collected in EMPHASIS-HF and formal tests for diabetes
were not performed.
Statistical methods
To assess the effect of eplerenone on new-onset diabetes in patients
without diabetes at baseline, the numbers of subjects developing dia-
betes in each treatment arm were compared in a univariate Cox pro-
portional hazard analysis, with treatment allocation (eplerenone or
placebo) as the only factor in the model. Cumulative event rates for
new-onset diabetes were compared using the log rank test. In an
attempt to exclude any potential effect of competing risk introduced
by an effect of eplerenone on mortality, an additional composite end-
point of all-cause mortality or new-onset diabetes was analysed.
To identify independent predictors of new-onset diabetes, data from
both treatment arms were pooled. Numerous commonly recorded
demographic, clinical, laboratory, and medication variables at baseline
were considered as predictors of diabetes (see Table 1). Patients
who did and did not develop diabetes during the trial were compared
with respect to these baseline variables using two-sample t-tests (for
continuous variables) and Fisher’s exact tests (for categorical vari-
ables). Univariate Cox proportional hazard analyses were employed
to assess the strength of association between each of these baseline
variables and new-onset diabetes. In subsequent multivariate Cox pro-
portional hazard analyses to identify independent predictors, two
approaches were used. In the first approach, a full multivariate Cox
proportional hazard model (Model 1) was built by including all vari-
ables associated with new-onset diabetes (P , 0.10 identified from
univariate Cox proportional hazard analyses) but for highly correlated
variables [e.g. body mass index (BMI), waist circumference, and weight]
only the variable that provided the most information was included. In
the second approach, a reduced multivariate model (Model 2) was
established from the full multivariate Cox proportional hazard model
(Model 1) using a stepwise selection process to identify relevant vari-
ables. For the univariate and multivariate analyses, hazard ratios (HRs)
for new-onset diabetes are provided per one standard deviation of
each continuous variable to facilitate comparison. Finally, receiver op-
erating characteristic (ROC) curve analysis was performed to calculate
the c-statistics for both Models 1 and 2.
All P-values were two sided, and P , 0.05 was considered statistic-
ally significant. Analyses were performed using Statistical Analysis
Software (SAS, Window Version V8).
Results
Of the 2737 patients randomized in EMPHASIS-HF, 891 (32.5%)
were known to have diabetes at baseline. Analyses in this report
are limited to the 1846 patients without known diabetes at baseline.
The average age was 69 years and average BMI was 27 kg/m2. During
the 21 months of follow-up, 69 (3.7%) of the 1846 patients without
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Table 1 Baseline characteristics of EMPHASIS-HF participants with mild heart failure and no history of diabetes at
baseline, split into those who did and did not develop diabetes during the trial
Variable No new-onset DM (SD or %)
n 5 1777
New-onset DM (SD or %)
n 5 69
P-value*
Age (years) 68.9 (7.8) 66.9 (7.2) 0.037
Gender (male) 1377 (77.5) 58 (84.1) 0.24
Race White 1523 (85.7) 64 (92.8) 0.35
Black 50 (2.8) 0 (0) –
Asian 151 (8.5) 3 (4.3) –
Other 50 (2.8) 2 (2.9) –
Smoking status Never 800 (45.0) 21 (30.4) 0.040
Current 202 (11.4) 8 (11.6) –
Previous 775 (43.6) 40 (58.0) –
HF aetiology: ischaemia 1160 (65.3) 45 (65.2) 1.00
Duration of HF (years) 4.4 (5.8) 6.0 (6.4) 0.021
Left ventricular ejection fraction (%) 25.9 (4.7) 26.5 (4.4) 0.38
Demographicsvitals BMI (kg/m2) 27.0 (4.6) 29.3 (4.9) 0.0001
SBP (mmHg) 123.3 (16.8) 129.0 (15.3) 0.0054
DBP (mmHg) 74.5 (10.2) 77.9 (9.0) 0.0061
Heart rate (b.p.m.) 72.5 (15.8) 77.7 (15.2) 0.0073
Waist circumference (cm) 97.8 (13.4) 104.0 (11.6) 0.0002
Weight (kg) 78.0 (16.2) 85.4 (15.4) 0.0002
Past medical history Hypertension 1098 (61.8) 53 (76.8) 0.0112
Previous MI 849 (47.8) 33 (47.8) 1.00
Atrial fibrillation 571 (32.1) 31 (44.9) 0.035
LBBB on ECG 444 (25.0) 15 (21.7) 0.67
QRS duration (ms) 122.9 (46.6) 121.4 (48.3) 0.79
Laboratory Albumin (g/dL) 4.1 (0.5) 4.1 (0.4) 0.80
ALT (IU/L) 27.2 (16.8) 34.9 (22.8) 0.0079
AST (IU/L) 26.7 (14.0) 31.7 (20.6) 0.052
Creatinine (mg/dL) 1.1 (0.3) 1.1 (0.3) 0.45
eGFR (mL/min/1.73 m2) 71.6 (21.7) 71.9 (18.8) 0.91
Potassium (mmol/L) 4.3 (0.4) 4.4 (0.4) 0.023
Bilirubin (mg/dL) 0.8 (0.4) 0.7 (0.3) 0.11
Medications ACE inhibitor 1429 (80.4) 56 (81.2) 1.00
ARB 316 (17.8) 17 (24.6) 0.15
Lipid-lowering agent 1094 (61.6) 41 (59.4) 0.71
ACE inhibitor or ARB 1699 (95.6) 69 (100) 0.12
Beta-blocker 1544 (86.9) 55 (79.7) 0.10
Digitalis 450 (25.3) 32 (46.4) 0.0002
Diuretic 1515 (85.3) 62 (89.9) 0.38
Data provided as n (%) or mean (SD).
ACE, angiotensin-converting enzyme; ALT, alanine aminotransferase; ARB, angiotensin receptor blocker; AST, aspartate aminotransferase; BMI, body mass index; DBP, diastolic
blood pressure; DM, diabetes mellitus; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; HF, heart failure; LBBB, left bundle branch block; MI, myocardial
infarction; SBP, systolic blood pressure.
*Based on two-sample t-tests for continuous variables and Fisher’s exact tests for categorical variables.
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diabetes at baseline were diagnosed with diabetes, an approximate
incidence of 21 cases per 1000 patient-years.
Effect of eplerenone on new-onset
diabetes
The baseline characteristics of patients without diabetes at baseline
were balanced between randomized treatment arms (Supplemen-
tary material online, Table S1). Eplerenone had no effect on the in-
cidence of new-onset diabetes; 33 (3.7%) of 894 patients assigned
to treatment with eplerenone developed diabetes compared with
36 (3.8%) of 952 patients assigned placebo (Figure 1). This corre-
sponded to a HR of 0.94 [95% confidence interval (CI) 0.59–
1.52, P ¼ 0.81]. The eplerenone:placebo HR for the composite
of all-cause mortality or new-onset diabetes was 0.80 (95% CI
0.64–1.01); P ¼ 0.06 (Figure 2).
Predictors of new-onset diabetes in mild
heart failure
The baseline characteristics of patients who did and did not
develop new diabetes are shown in Table 1. In univariate Cox pro-
portional hazard analysis, the strongest predictors of new-onset
diabetes (in decreasing order of magnitude as estimated by the
Wald x2 statistic) were: higher serum alanine aminotransferase
(ALT), use of digitalis, higher serum aspartate aminotransferase
(AST), higher waist circumference, higher weight, higher BMI,
Figure 1 Kaplan–Meier plot for new-onset diabetes on epler-
enone compared with placebo in EMPHASIS-HF.
Figure 2 Kaplan–Meier plot for the composite endpoint of
new-onset diabetes or mortality on eplerenone compared with
placebo in EMPHASIS-HF.
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Table 2 Association of baseline characteristics with
new-onset diabetes using univariate Cox proportional
hazard analysis (expressed per one standard deviation







ALT (IU/L) 16.79 1.39 (1.19–1.62) ,0.0001
Digitalis 15.01 2.55 (1.59–4.09) 0.0001
AST (IU/L) 14.78 1.36 (1.16–1.60) 0.0001
Waist circumference
(cm)
13.09 1.54 (1.22–1.95) 0.0003
Weight (kg) 11.99 1.49 (1.19–1.86) 0.0005
BMI (kg/m2) 11.47 1.43 (1.16–1.77) 0.0007




7.02 2.00 (1.20–3.34) 0.0081
Heart rate (b.p.m.) 6.87 1.30 (1.07–1.59) 0.0088
Hypertension 6.27 2.04 (1.17–3.57) 0.012
SBP (mmHg) 6.10 1.34 (1.06–1.69) 0.0135
Age (years) 5.97 0.72 (0.55–0.94) 0.015
DBP (mmHg) 5.70 1.33 (1.05–1.68) 0.017
Potassium (mmol/L) 4.52 1.32 (1.02–1.70) 0.034
Beta-blocker 4.10 0.55 (0.30–0.98) 0.043
Atrial fibrillation 3.97 1.62 (1.01–2.60) 0.046
ARB 2.32 1.53 (0.89–2.65) 0.13
Gender (male vs.
female)
1.64 1.52 (0.80–2.90) 0.20
Bilirubin (mg/dL) 1.48 0.83 (0.61–1.12) 0.22
Race (white vs. other) 0.85 1.53 (0.62–3.82) 0.36
LBBB on ECG 0.55 0.81 (0.45–1.43) 0.46
LVEF (%) 0.54 1.10 (0.85–1.44) 0.46
Creatinine (mg/dL) 0.30 0.93 (0.73–1.20) 0.59
Lipid-lowering agent 0.15 0.91 (0.56–1.47) 0.70
Previous MI 0.12 1.09 (0.68–1.75) 0.73
ACE inhibitor 0.11 0.90 (0.49–1.65) 0.74
Albumin (g/dL) 0.076 0.97 (0.76–1.23) 0.78
Heart failure aetiology
(ischaemia vs. other)
0.036 0.95 (0.58–1.56) 0.85
QRS duration (ms) 0.029 1.02 (0.81–1.28) 0.87
eGFR (mL/min/
1.73 m2)
0.005 0.99 (0.78–1.27) 0.94
The x2 statistic, hazard ratio, 95% CI, and P-values are based on univariate Cox
proportional hazard analysis.
ACE, angiotensin-converting enzyme; ALT, alanine aminotransferase; ARB,
angiotensin receptor blocker; AST, aspartate aminotransferase; BMI, body mass
index; CI, confidence interval; DBP, diastolic blood pressure; ECG,
electrocardiogram; eGFR, estimated glomerular filtration rate; HF, heart failure;
LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; MI,
myocardial infarction; SBP, systolic blood pressure.
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longer duration of heart failure, current or previous smoking,
higher heart rate, hypertension, higher systolic blood pressure,
lower age, higher diastolic blood pressure, higher serum potassium,
not using a beta-blocker. and the presence of atrial fibrillation (see
Table 2).
In multivariable Cox proportional hazard analysis, Model 1 [full
model where only variables with P , 0.10 in univariate analysis
were included but for the following groups of highly correlated
variables only the variable that provided the most information
was included: (i) systolic and diastolic blood pressure: systolic
blood pressure selected; (ii) weight, waist circumference, and
BMI: waist circumference selected; (iii) ALT and AST: ALT
selected], only seven variables remained significantly associated
with new-onset diabetes (see Table 3). These independent predic-
tors of new-onset diabetes (in decreasing order of magnitude as
estimated by the Wald x2 statistic) were: use of digitalis, higher
serum ALT, longer heart failure duration, current or previous
smoking, higher waist circumference, lower age, and higher systolic
blood pressure. Variables identified in Model 2 (the reduced
model) were similar.
In the ROC curve analysis, the individual c-statistic for variables
independently associated with new-onset diabetes varied from
0.53 to 0.65 in Models 1 and 2. When all the relevant variables
were combined, the overall c-statistic was 0.74 for Model 1 and
0.76 for Model 2 (see Table 4).
Discussion
That diabetes is common in patients with heart failure1 was con-
firmed in the present study. Thirty-two per cent of participants
had diabetes at baseline, and in those without diabetes at baseline
the incidence of new diabetes was 21 cases per 1000 patient-years
of follow-up. This incidence is similar to that reported in two other
clinical trials in chronic heart failure2,3 and is considerably higher
than expected in the general population, e.g. the incidence of
physician-diagnosed diabetes was 12.8 cases per 1000 patient-years
in American adults aged 65–79 years in 2009.14
The effect of MR antagonists on the risk of diabetes is difficult to
predict. Primary hyperaldosteronism is a state of insulin resistance,
and aldosterone levels are associated with insulin resistance in
normotensive and hypertensive patients.15 In an observational
study of patients with primary hyperaldosteronism, treatment
with either spironolactone or adrenalectomy returned insulin sen-
sitivity parameters towards normal.16 In another study, the com-
bination of vitamin E and spironolactone for 8 weeks decreased
insulin levels and Homeostasis Model Assessment of Insulin Resist-
ance (HOMA-IR) compared with vitamin E alone in patients with
biopsy-proven NAFLD,11 while spironolactone therapy has
shown benefical cardiac effects in patients with metabolic syn-
drome.17 Low serum potassium is also known to be associated
with increased risk of new-onset diabetes in both normotensive
and treated hypertensive patients, and MR antagonists increase po-
tassium.18,19 On the other hand, spironolactone therapy has con-
sistently led to modest increases in HbA1c in clinical trials of
patients with type 2 diabetes alone or complicated by nephropathy
or poorly controlled hypertension.8– 10 In a further study of 107
patients with mild chronic heart failure, spironolactone therapy
increased HbA1c and cortisol levels and reduced adiponectin
levels over 4 months,7 findings which might be expected to
herald an increased risk of developing diabetes. In contrast, in
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Table 3 Prediction of new-onset diabetes in patients with mild heart failure using multivariate Cox proportional hazard
analysis (expressed per one standard deviation for continuous variables)
Variable Multivariate Cox proportional hazards
(Model 1)
Multivariate Cox model with stepwise
selection (Model 2)
x2 Hazard ratio (95% CI) P-value x2 Hazard ratio (95% CI) P-value
Digitalis 9.88 2.37 (1.38–4.06) 0.002 14.30 2.59 (1.58–4.24) 0.0002
ALT (IU/L) 9.49 1.36 (1.12–1.64) 0.002 10.59 1.36 (1.13–1.63) 0.001
Heart failure duration (years) 9.06 1.38 (1.12–1.69) 0.003 9.87 1.39 (1.13–1.71) 0.002
Smoking (current/past vs. never) 6.25 1.99 (1.16–3.41) 0.012 5.85 1.93 (1.13–3.28) 0.016
Waist circumference (cm) 5.78 1.38 (1.06–1.79) 0.016 10.58 1.51 (1.18–1.93) 0.001
Age (years) 5.18 0.71 (0.53–0.95) 0.023 4.52 0.73 (0.55–0.98) 0.034
SBP (mmHg) 4.64 1.32 (1.03–1.69) 0.031 7.18 1.38 (1.09–1.75) 0.007
Hypertension 2.78 1.67 (0.91–3.06) 0.10 – – –
Potassium (mmol/L) 2.29 1.22 (0.94–1.59) 0.13 – – –
Heart rate (b.p.m.) 1.59 1.16 (0.92–1.45) 0.21 – – –
Beta-blockers 0.71 0.75 (0.39–1.46) 0.40 – – –
Atrial fibrillation 0.16 1.12 (0.65–1.94) 0.69 – – –
The x2 statistic, hazard ratio, 95% CI, and P-values are based on multivariate Cox proportional hazard analysis including all predictor variables with P , 0.10 in univariate analysis.
For the following highly correlated variables, the following variables were selected by a stepwise process:
†Systolic and diastolic blood pressure: systolic blood pressure included.
†Weight, waist circumference. and BMI: waist circumference selected.
†ALT and AST: ALT selected.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CI, confidence interval; SBP, systolic blood pressure.
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that study eplerenone had no such effects, suggesting the possibil-
ity of a differential effect, depending on the selectivity of MR block-
ade. Consistent with this, we found no effect of eplerenone on
incident diabetes in the present study, although the number of
affected patients was relatively small.
We identified seven factors independently associated with new-
onset diabetes. Of these, longer duration of heart failure, higher
serum ALT, and higher waist circumference were expected predic-
tors. Serum ALT has been associated with incident diabetes in a
number of studies in several different populations, including heart
failure.2,20,21 Usually this is thought to be because ALT is consid-
ered a surrogate marker for NAFLD, a condition characterized
by insulin resistance and therefore a powerful risk factor for dia-
betes. Whether or not this is the explanation in heart failure is
less certain because transaminases may be elevated due to liver
congestion or ischaemia. Interestingly, waist circumference per-
formed slightly better as a predictor compared with either BMI
or body weight. Digitalis was strongly predictive of new-onset dia-
betes, a finding noted in earlier studies but unexplained.2,3 One
possibility is that digitalis use is a marker of heart failure severity,
and there is some evidence that the risk of diabetes increases
with increasing severity of heart failure.22 However, it has also
been suggested that reduced activity of Na/K-ATPase may play a
role in the pathogenesis of diabetes mellitus, and digoxin is an in-
hibitor of this enzyme.23,24 Lower age was also associated with
higher risk of developing diabetes. Though at first sight surprising,
this was noted in previous studies2,3 and seems likely to reflect
either the different phenotypes of older and younger trial partici-
pants [data exist to support this: in a substudy of 2107 patients
in CHARM, the prevalence of obesity (BMI ≥ 30 kg/m2) was
four times higher in patients with chronic heart failure aged ,50
years than in patients aged ≥ 80 years] or the longer survival of
younger participants recruited in trials of chronic heart failure
patients. When the independent variables were combined in pre-
dictive models, they provided reasonable c-statistics of 0.74–
0.76. Indeed, this is comparable with models for prediction of dia-
betes in the general population, despite not containing any direct
glucose-related measures.25
Various strengths and weaknesses of the data contained in this
report warrant discussion. This is the first randomized trial to
report the effect of MR antagonist therapy on new-onset diabetes,
and participants were well phenotyped at baseline. While diabetes
was physician-diagnosed and not based on trial-required measure-
ments of fasting plasma glucose, participants were specifically asked
about new-onset diabetes at each trial visit. Data for family history
of diabetes were not available. The numbers of participants that
developed diabetes was relatively small, so statistical power to
detect a modest effect of eplerenone on new-onset diabetes was
limited.
In summary, information available from commonly measured
clinical and laboratory variables predicts the development of new-
onset diabetes in patients with symptomatically mild systolic heart
failure with similar accuracy to models used in other populations.
Treatment of these patients with eplerenone had no effect on
the development of diabetes compared with placebo.
Supplementary material
Supplementary material is available at European Journal of Heart
Failure online.
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Table 4 Prediction of new-onset diabetes in patients with mild heart failure using receiver operating characteristic
curve analysis for variables associated with new-onset diabetes
Variable Multivariate model 1 Multivariate model 2
c-statistic (95% CI) P-value c-statistic (95% CI) P-value
Age (years) 0.586 (0.517–0.656) 0.014 0.586 (0.517–0.656) 0.014
Smoking (current/past vs. never) 0.571 (0.513–0.629) 0.016 0.571 (0.513–0.629) 0.016
SBP (mmHg) 0.599 (0.535–0.664) 0.0026 0.599 (0.535–0.664) 0.0026
Waist circumference (cm) 0.650 (0.586–0.714) ,0.0001 0.650 (0.586–0.714) ,0.0001
ALT (IU/L) – – 0.596 (0.524–0.668) 0.0035
AST (IU/L) 0.563 (0.486–0.639) 0.11 – –
Heart failure duration (years) 0.566 (0.489–0.643) 0.093 0.566 (0.489–0.643) 0.093
Digitalis 0.600 (0.538–0.662) 0.0015 0.600 (0.538–0.662) 0.0015
Hypertension 0.567 (0.512–0.621) 0.0158 – –
Potassium (mmol/L) 0.572 (0.501–0.643) 0.0464 – –
Heart rate (b.p.m.) 0.613 (0.546–0.680) 0.0010 – –
Beta-blockers 0.527 (0.479–0.575) 0.2706 – –
Atrial fibrillation 0.567 (0.504–0.629) 0.0357 – –
Combined c-statistic 0.764 (0.708–0.821) ,0.0001 0.735 (0.673–0.797) ,0.0001
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; SBP, systolic blood pressure.
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